Prudential Financial’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-42,861
| Closed | -$427K | – | 2481 |
|
|
2025
Q2 | $427K | Sell |
42,861
-27,840
| -39% | -$224K | ﹤0.01% | 1985 |
|
|
2025
Q1 | $422K | Sell |
70,701
-161,390
| -70% | -$1.18M | ﹤0.01% | 1896 |
|
|
2024
Q4 | $1.78M | Sell |
232,091
-21,200
| -8% | -$182K | ﹤0.01% | 1346 |
|
|
2024
Q3 | $2.59M | Buy |
253,291
+22,800
| +10% | +$348K | ﹤0.01% | 1338 |
|
|
2024
Q2 | $3.42M | Sell |
230,491
-11,400
| -5% | -$163K | 0.01% | 1093 |
|
|
2024
Q1 | $3.3M | Sell |
241,891
-101,100
| -29% | -$1.1M | ﹤0.01% | 1164 |
|
|
2023
Q4 | $3.76M | Buy |
342,991
+91,290
| +36% | +$905K | 0.01% | 1088 |
|
|
2023
Q3 | $2.76M | Sell |
251,701
-39,350
| -14% | -$503K | ﹤0.01% | 1188 |
|
|
2023
Q2 | $3.85M | Buy |
291,051
+133,690
| +85% | +$1.91M | 0.01% | 1034 |
|
|
2023
Q1 | $2.14M | Buy |
157,361
+11,300
| +8% | +$202K | ﹤0.01% | 1298 |
|
|
2022
Q4 | $2.85M | Buy |
146,061
+1,200
| +0.8% | +$23.4K | ﹤0.01% | 1138 |
|
|
2022
Q3 | $2.76M | Buy |
144,861
+32,355
| +29% | +$745K | ﹤0.01% | 1139 |
|
|
2022
Q2 | $2.32M | Sell |
112,506
-54,115
| -32% | -$1.28M | ﹤0.01% | 1313 |
|
|
2022
Q1 | $5.36M | Buy |
166,621
+109,991
| +194% | +$4M | 0.01% | 952 |
|
|
2021
Q4 | $2.64M | Buy |
+56,630
| New | +$1.89M | ﹤0.01% | 1381 |
|
Other funds holding ITOS
Prudential Financial's ITOS Position: Q3 2025 in Review
Prudential Financial sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 42,861 shares — an estimated $427K sold.
Prudential Financial first reported a position in ITOS in Q4 2021 and held it in 15 quarters. The position peaked at $5.36M in Q1 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Prudential Financial reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Prudential Financial sold 42,861 iTeos Therapeutics shares in Q3 2025, an estimated $427K.
- Prudential Financial first reported a position in iTeos Therapeutics in Q4 2021 and held it in 15 quarters.
- Prudential Financial's iTeos Therapeutics position peaked at $5.36M in Q1 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Prudential Financial's 13F filing for Q3 2025, filed 13 Nov 2025.